Skip to main content

NBTX · Nanobiotix S.A. · Documents

Track NBTX — free
$26.50 -0.82 (-2.98%) At close · Nov 20 Play latest call Q4 2025 earnings call transcript
Market Cap
$1.35B
Shares
50.95M
Volume · Nov 20 125.29K Avg daily vol (3M) 147.83K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue 32.59M EUR 20-F filed Mar 31, 2026 Earnings call Q4 2025 earnings call Held Dec 31, 2025
2026
Nov 9
Current report 6-K
November investor conference appearances announced

NANOBIOTIX announced management appearances at the Jefferies Global Healthcare Conference on Monday, November 16, 2026, and the UBS Global Biopharma Conference on Tuesday, November 17, 2026, in London.

7 source passages
NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in the following investor conferences in November: Jefferies Global Healthcare Conference in London Date: Monday, November 16, 2026 Location: London (UK) UBS Global Biopharma Conference Date: Tuesday, November 17, 2026 Location: London (UK) Open the document at this passage
Oct 26
Current report 6-K
Melanoma study shows 41.7% overall response rate with JNJ-1900

Nanobiotix reported final Phase 1 data for JNJ-1900 (NBTXR3) with immune checkpoint inhibitors in anti-PD-1-resistant primary cutaneous melanoma. The overall response rate was 41.7% (10/24), including 4 complete responses, with median overall survival of 17.8 months.

3 source passages
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma 41.7% (10/24) overall response rate (ORR) per RECIST 1.1, including 4 complete responses 17.8 months median Overall Survival Open the document at this passage
Oct 1
Current report 6-K
Current report

Nanobiotix S.A. appointed Arnd Christ chief financial officer and executive board member effective October 1, 2026; Bart Van Rhijn will step down as chief financial & business officer and board member after five years.

Sep 24
Current report 6-K
Current report

Nanobiotix reported a €34.3 million net loss for the six months ended June 30, 2026, with €110.9 million in cash and cash equivalents. Its May 2026 Global Offering raised approximately $100 million (corresponding to €86.1 million) gross and €80.1 million net.

Read from the first part of this long document
Sep 24
Current report 6-K
Current report

Nanobiotix reported €110.9 million in cash and cash equivalents as of June 30, 2026, funding operations into 2029.

Sep 22
Current report 6-K
Current report

Nanobiotix S.A. reported 50,941,528 shares outstanding as of August 31, 2026, with 54,701,246 theoretical voting rights and 54,679,128 exercisable voting rights.

Mar 31
Annual report 20-F FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue 32.59M EUR Net loss 23.96M EUR Diluted EPS -0.50 EUR
2025
Showing 1–50 of 253 documents
Key facts CIK 1760854 CUSIP 63009J107 13F (30d) 27 filings 25 filers Visit website Investor relations